The ASH choosing wisely® campaign: Five hematologic tests and treatments to question

Lisa K. Hicks, Harriet Bering, Kenneth R. Carson, Judith Kleinerman, Vishal Kukreti, Alice Ma, Brigitta U. Mueller, Sarah H. O'Brien, Marcelo Pasquini, Ravindra Sarode, Lawrence Solberg, Adam E. Haynes, Mark A. Crowther

Research output: Contribution to journalArticle

79 Citations (Scopus)

Abstract

Choosing Wisely®is a medical stewardship and quality improvement initiative led by the American Board of Internal Medicine Foundation in collaboration with leading medical societies in the United States. The ASH is an active participant in the Choosing Wisely® project. Using an iterative process and an evidence-based method, ASH has identified 5 tests and treatments that in some circumstances are not well supported by evidence and which in certain cases involve a risk of adverse events and financial costs with low likelihood of benefit. The ASH Choosing Wisely® recommendations focus on avoiding liberal RBC transfusion, avoiding thrombophilia testing in adults in the setting of transient major thrombosis risk factors, avoiding inferior vena cava filter usage except in specified circumstances, avoiding the use of plasma or prothrombin complex concentrate in the nonemergent reversal of vitamin K antagonists, and limiting routine computed tomography surveillance after curativeintent treatment of non-Hodgkin lymphoma. We recommend that clinicians carefully consider anticipated benefits of the identified tests and treatments before performing them.

Original languageEnglish (US)
Pages (from-to)3879-3883
Number of pages5
JournalBlood
Volume122
Issue number24
DOIs
StatePublished - Dec 5 2013

Fingerprint

Vena Cava Filters
Thrombophilia
Vitamin K
Medical Societies
Hematologic Tests
Internal Medicine
Quality Improvement
Non-Hodgkin's Lymphoma
Thrombosis
Tomography
Costs and Cost Analysis
Plasmas
Testing
Costs
prothrombin complex concentrates

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Hicks, L. K., Bering, H., Carson, K. R., Kleinerman, J., Kukreti, V., Ma, A., ... Crowther, M. A. (2013). The ASH choosing wisely® campaign: Five hematologic tests and treatments to question. Blood, 122(24), 3879-3883. https://doi.org/10.1182/blood-2013-07-518423

The ASH choosing wisely® campaign : Five hematologic tests and treatments to question. / Hicks, Lisa K.; Bering, Harriet; Carson, Kenneth R.; Kleinerman, Judith; Kukreti, Vishal; Ma, Alice; Mueller, Brigitta U.; O'Brien, Sarah H.; Pasquini, Marcelo; Sarode, Ravindra; Solberg, Lawrence; Haynes, Adam E.; Crowther, Mark A.

In: Blood, Vol. 122, No. 24, 05.12.2013, p. 3879-3883.

Research output: Contribution to journalArticle

Hicks, LK, Bering, H, Carson, KR, Kleinerman, J, Kukreti, V, Ma, A, Mueller, BU, O'Brien, SH, Pasquini, M, Sarode, R, Solberg, L, Haynes, AE & Crowther, MA 2013, 'The ASH choosing wisely® campaign: Five hematologic tests and treatments to question', Blood, vol. 122, no. 24, pp. 3879-3883. https://doi.org/10.1182/blood-2013-07-518423
Hicks LK, Bering H, Carson KR, Kleinerman J, Kukreti V, Ma A et al. The ASH choosing wisely® campaign: Five hematologic tests and treatments to question. Blood. 2013 Dec 5;122(24):3879-3883. https://doi.org/10.1182/blood-2013-07-518423
Hicks, Lisa K. ; Bering, Harriet ; Carson, Kenneth R. ; Kleinerman, Judith ; Kukreti, Vishal ; Ma, Alice ; Mueller, Brigitta U. ; O'Brien, Sarah H. ; Pasquini, Marcelo ; Sarode, Ravindra ; Solberg, Lawrence ; Haynes, Adam E. ; Crowther, Mark A. / The ASH choosing wisely® campaign : Five hematologic tests and treatments to question. In: Blood. 2013 ; Vol. 122, No. 24. pp. 3879-3883.
@article{5822b1584f364f5c901b988cae38541e,
title = "The ASH choosing wisely{\circledR} campaign: Five hematologic tests and treatments to question",
abstract = "Choosing Wisely{\circledR}is a medical stewardship and quality improvement initiative led by the American Board of Internal Medicine Foundation in collaboration with leading medical societies in the United States. The ASH is an active participant in the Choosing Wisely{\circledR} project. Using an iterative process and an evidence-based method, ASH has identified 5 tests and treatments that in some circumstances are not well supported by evidence and which in certain cases involve a risk of adverse events and financial costs with low likelihood of benefit. The ASH Choosing Wisely{\circledR} recommendations focus on avoiding liberal RBC transfusion, avoiding thrombophilia testing in adults in the setting of transient major thrombosis risk factors, avoiding inferior vena cava filter usage except in specified circumstances, avoiding the use of plasma or prothrombin complex concentrate in the nonemergent reversal of vitamin K antagonists, and limiting routine computed tomography surveillance after curativeintent treatment of non-Hodgkin lymphoma. We recommend that clinicians carefully consider anticipated benefits of the identified tests and treatments before performing them.",
author = "Hicks, {Lisa K.} and Harriet Bering and Carson, {Kenneth R.} and Judith Kleinerman and Vishal Kukreti and Alice Ma and Mueller, {Brigitta U.} and O'Brien, {Sarah H.} and Marcelo Pasquini and Ravindra Sarode and Lawrence Solberg and Haynes, {Adam E.} and Crowther, {Mark A.}",
year = "2013",
month = "12",
day = "5",
doi = "10.1182/blood-2013-07-518423",
language = "English (US)",
volume = "122",
pages = "3879--3883",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "24",

}

TY - JOUR

T1 - The ASH choosing wisely® campaign

T2 - Five hematologic tests and treatments to question

AU - Hicks, Lisa K.

AU - Bering, Harriet

AU - Carson, Kenneth R.

AU - Kleinerman, Judith

AU - Kukreti, Vishal

AU - Ma, Alice

AU - Mueller, Brigitta U.

AU - O'Brien, Sarah H.

AU - Pasquini, Marcelo

AU - Sarode, Ravindra

AU - Solberg, Lawrence

AU - Haynes, Adam E.

AU - Crowther, Mark A.

PY - 2013/12/5

Y1 - 2013/12/5

N2 - Choosing Wisely®is a medical stewardship and quality improvement initiative led by the American Board of Internal Medicine Foundation in collaboration with leading medical societies in the United States. The ASH is an active participant in the Choosing Wisely® project. Using an iterative process and an evidence-based method, ASH has identified 5 tests and treatments that in some circumstances are not well supported by evidence and which in certain cases involve a risk of adverse events and financial costs with low likelihood of benefit. The ASH Choosing Wisely® recommendations focus on avoiding liberal RBC transfusion, avoiding thrombophilia testing in adults in the setting of transient major thrombosis risk factors, avoiding inferior vena cava filter usage except in specified circumstances, avoiding the use of plasma or prothrombin complex concentrate in the nonemergent reversal of vitamin K antagonists, and limiting routine computed tomography surveillance after curativeintent treatment of non-Hodgkin lymphoma. We recommend that clinicians carefully consider anticipated benefits of the identified tests and treatments before performing them.

AB - Choosing Wisely®is a medical stewardship and quality improvement initiative led by the American Board of Internal Medicine Foundation in collaboration with leading medical societies in the United States. The ASH is an active participant in the Choosing Wisely® project. Using an iterative process and an evidence-based method, ASH has identified 5 tests and treatments that in some circumstances are not well supported by evidence and which in certain cases involve a risk of adverse events and financial costs with low likelihood of benefit. The ASH Choosing Wisely® recommendations focus on avoiding liberal RBC transfusion, avoiding thrombophilia testing in adults in the setting of transient major thrombosis risk factors, avoiding inferior vena cava filter usage except in specified circumstances, avoiding the use of plasma or prothrombin complex concentrate in the nonemergent reversal of vitamin K antagonists, and limiting routine computed tomography surveillance after curativeintent treatment of non-Hodgkin lymphoma. We recommend that clinicians carefully consider anticipated benefits of the identified tests and treatments before performing them.

UR - http://www.scopus.com/inward/record.url?scp=84891119402&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84891119402&partnerID=8YFLogxK

U2 - 10.1182/blood-2013-07-518423

DO - 10.1182/blood-2013-07-518423

M3 - Article

C2 - 24307720

AN - SCOPUS:84891119402

VL - 122

SP - 3879

EP - 3883

JO - Blood

JF - Blood

SN - 0006-4971

IS - 24

ER -